Article

Less demanding famciclovir regimen compares with acyclovir

Galveston, TX-Three-times-a-day treatment with famciclovir (Famvir, Novartis) was as effective against ophthalmic herpes zoster as five-times-a-day acyclovir (Zovirax, Glaxo Wellcome) in a major international trial, said Stephen K. Tyring, MD, PhD.

Related Videos
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Image credit: ©Ophthalmology Times
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
(Image credit: AdobeStock/InsideCreativeHouse)
February 19th 2025

Alcon announces US launch of Voyager direct selective laser trabeculoplasty device

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/Syda Productions)
February 12th 2025

Meibomian gland dysfunction in younger populations: why early detection is critical

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

(Image credit: AdobeStock/Natallia)
February 6th 2025

Treating systemic inflammation may protect against diabetes

(Image credit: AdobeStock/Vitalii Vodolazskyi)
February 6th 2025

Exploring presbyopia progression in patients with glaucoma treated with PF receptor agonists

© 2025 MJH Life Sciences

All rights reserved.